Bcli stock target price

Jan 01, 2010 · BRAINSTORM CELL THER (BCLI) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers on Benzinga. How Has Brainstorm Cell Therapeutics Inc (BCLI) Stock's ... Mar 03, 2020 · BCLI's rank also includes a short-term technical score of 94. The fundamental score for BCLI is 78. In addition to the average rating from Wall Street analysts, BCLI stock has a mean target price of 12.833. This means analysts expect the stock to increase 93.56% over the next 12 months. Brainstorm Cell Therapeutics In (BCLI) Stock Forum ... Find the latest Brainstorm Cell Therapeutics In (BCLI) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. Brainstorm Cell Therapeutics Inc. - TheStreet

Brainstorm Cell Therapeutics Inc. Common Stock (BCLI) Real ...

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. BCLI Stock News and Price / BrainStorm Cell Therapeutics ... Up to $50,000,000 Common Stock This prospectus supplement and the accompanying prospectus relate to the offer and sale from time to time of shares of our common stock, par value $0.00005 per share, having an aggregate offering price of up to $50,000,000. BCLI Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded to Buy ... ValuEngine upgraded shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) from a hold rating to a buy rating in a research report report published on …

BCLI shares outstanding history table and chart, presented by SharesOutstandingHistory.com. -32.31% CAGR BCLI Historical Shares Outstanding: +-32.31% CAGR BCLI Stock Price Chart 10 ETFs With Most Upside To Analyst Targets

Analyst price targets provided by TipRanks. Quick Links. Advanced Charting · After Hours Quote · Analyst Research  Their average twelve-month price target is $9.00, suggesting that the stock has a possible upside of 93.55%. The high price target for BCLI is $9.00 and the low  According to analysts' consensus price target of $9.00, Brainstorm Cell Therapeutics has a potential upside of 87.1% from its current price of $4.81. Amount of